A Phase II, Single‐Arm, Open‐Label, Bayesian Adaptive Efficacy and Safety Study of PBI‐05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma

LESSONS LEARNED: This trial evaluating a novel plant extract, PBI‐05204, did not meet its primary endpoint of overall survival but did show signals of efficacy in heavily pretreated mPDA. PBI‐05204 was generally well tolerated, with the most common side effects related to treatment being vomiting (2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Roth, Marc T., Cardin, Dana Backlund, Borazanci, Erkut Hasan, Steinbach, Margaux, Picozzi, Vincent J., Rosemury, Alexander, Wadlow, Raymond Couric, Newman, Robert A., Berlin, Jordan
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2020
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543353/
https://ncbi.nlm.nih.gov/pubmed/32452588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0440
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge